The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global preclinical CRO market reached a value of US$ 4.6 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A preclinical contract research organization (CRO) is a support center that provides expertise in research and development (R&D). It ensures that a medication or therapeutic gadget is sheltered and successfully developed before being launched in the market. It offers services that assist in clearing a pharmaceutical item through animal testing and advancing it to the clinical phase. Moreover, it provides critical studies to researchers, restorative workforce, different industries and legislative contacts for assessing drug efficacy and safety in animal models and completing Investigational New Drug (IND) filing studies.
The emerging trend of outsourcing represents one of the key factors impelling the market growth. Apart from this, preclinical CROs offer end-to-end services, such as toxicology testing, which is also contributing to the market growth. Furthermore, the market has witnessed a significant change in the process of drug approval by the Food and Drug Administration (FDA). The process now subjects the drug candidate to preclinical studies for establishing its safety and effectivity among humans before the approval. Besides this, the 21st Century Cures Act was passed by the United States Congress in 2016 to accelerate medical product development and fasten the approval process for the launch of medical devices and drugs. These initiatives are positively influencing the demand for preclinical CRO services. Other major factors, including the readily available skilled human resources, low cost of devices, and the increasing prevalence of chronic diseases, are anticipated to fuel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global preclinical CRO market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on service and end use.
Breakup by Service:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories Inc., Covance Inc. (Laboratory Corporation of America Holdings), Eurofins Scientific, ICON Plc, MD Biosciences Inc. (MLM Medical Labs), Medpace, Parexel International Corporation, PPD Inc. and Wuxi AppTec.
|Base Year of the Analysis||2020|
|Segment Coverage||Service, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Charles River Laboratories Inc., Covance Inc. (Laboratory Corporation of America Holdings), Eurofins Scientific, ICON Plc, MD Biosciences Inc. (MLM Medical Labs), Medpace, Parexel International Corporation, PPD Inc. and Wuxi AppTec|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at